ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
CT characteristics of solitary pulmonary capillary hemangioma versus lung adenocarcinoma.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundSolitary pulmonary capillary hemangioma is an underrecognized rare benign disease that can radiologically mimic lung adenocarcinoma. This study aims to demonstrate radiologic features of SPCH and compare characteristics between SPCH and lung adenocarcinoma. MATERIALS AND
methodsThis retrospective study included all histologically confirmed SPCH cases from our institution between July 2015 and December 2024. For comparison, lung adenocarcinomas matched to SPCH by nodule consistency and size within the same period were included. Two chest radiologists independently assessed each nodule’s consistency, size, location, and morphologic signs, with group comparisons by χ² or Fisher exact tests and Mann-Whitney U tests.
resultsThe study comprised 44 SPCH patients (28 women, 63.6%; median age, 44.5 years [IQR, 37.0–55.2]) and 352 adenocarcinoma patients (202 women, 57.4%; median age, 58 years [IQR,50.0–65.0]). SPCH can manifest as nonsolid (12/44, 27.3%), part-solid (8/44, 18.2%) and solid nodules (24/44, 54.5%). SPCH shared multiple features with lung adenocarcinoma in nonsolid and part-solid nodules. However, in solid nodules, SPCH were more likely to occur in lower lobes (21/24, [87.5%] vs. 71/192 [37%]), more often presented with air bronchogram (18/24 [75.0%] vs. 26/192 [13.5%]), and lacked spiculation (2/24 [8.3%] vs. 169/192, [88.0%]) and pleural retraction (5/24, [20.8%] vs. 131/192, [68.2%]) (all P < 0.001). Five SPCH cases (5/44, 11.3%) demonstrated atypical bronchus lucency, while 3 cases (3/44, 6.8%) showed perivascular lucency.
conclusionSolid SPCHs are distinguished from lung adenocarcinomas by a predilection for peripheral lower-lobe location, frequent air bronchograms, and near-absence of spiculation or pleural retraction. Recognition of atypical bronchus lucency and perivascular lucency signs may further aid differentiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.